Sivik Global Healthcare LLC Acquires Shares of 7,000 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sivik Global Healthcare LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 7,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,647,000.

Several other institutional investors and hedge funds have also made changes to their positions in ALNY. Huntington National Bank lifted its holdings in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares in the last quarter. Hollencrest Capital Management purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $29,000. R Squared Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $33,000. Washington Trust Advisors Inc. purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at about $42,000. Finally, True Wealth Design LLC grew its stake in Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on ALNY. Barclays upped their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Chardan Capital reiterated a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. StockNews.com lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Finally, Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $298.61.

Alnylam Pharmaceuticals Stock Up 0.7 %

Shares of ALNY stock opened at $275.94 on Thursday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The business’s fifty day moving average is $249.42 and its 200-day moving average is $260.65. The stock has a market cap of $35.59 billion, a PE ratio of -105.42 and a beta of 0.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The company’s revenue was down 33.3% compared to the same quarter last year. During the same period last year, the firm earned $1.15 earnings per share. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at $3,416,865. This represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 73,964 shares of company stock worth $20,622,925 in the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.